| 1. |
- Berzisa, Solvita, et al.
(författare)
-
Capability Driven Development : An Approach to Designing Digital Enterprises
- 2015
-
Ingår i: Business & Information Systems Engineering. - : Springer Science and Business Media LLC. - 2363-7005 .- 1867-0202. ; 57:1, s. 15-25
-
Tidskriftsartikel (refereegranskat)abstract
- The need for organizations to operate in changing environments is addressed by proposing an approach that integrates organizational development with information system (IS) development taking into account changes in the application context of the solution. This is referred to as Capability Driven Development (CDD). A meta-model representing business and IS designs consisting of goals, key performance indicators, capabilities, context and capability delivery patterns, is being proposed. The use of themeta-model is validated in three industrial case studies as part of an ongoing collaboration project, whereas one case is presented in the paper. Issues related to the use of the CDD approach, namely, CDD methodology and tool support are also discussed.
|
|
| 2. |
- Bravos, George, et al.
(författare)
-
Deliverable 1.2 : Initial version of requirements specification for CDD
- 2013
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- The CaaS project will elaborate the Capability Driven Development (CDD) approach that will allow digital enterprises to exploit the notion of 'capability' as a means of both designing for services and with services. This deliverable defines an initial set of requirements for CDD. These requirements are provided by the industrial partners through exploration of their use cases. The goal of this deliverable is to identify potential benefits that the CaaS approach could bring to the use cases as well the features to be included the CDD methodology. The requirements are elicited from the use case partners during semi-structured interviews. They are documented in a form of goal models, actor models and concept models for each partner separately. Information documented in these models is used to define envisioned capabilities to be design and delivered during the project as well as to establish the scope of each use case. The use case scope definition focuses on use case goals, causes of capability delivery variability, capability delivery context, functions to be provided in the use case as well as potential capability delivery adjustments. The use case specific models are combined together to obtain a preliminary set of general requirements for CDD. These requirements show CDD goals, types of stakeholders, types of context and types of adjustments. The deliverable ends with concluding remarks about the partners’ expectations for CDD. The requirements for the use cases described in this deliverable will be further elaborated in the final requirements document deliverable D1.4 and will be iteratively refined during the use case elaboration performed in work packages WP2, WP3 and WP4.
|
|
| 3. |
- Gretarsdottir, Solveig, et al.
(författare)
-
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm
- 2010
-
Ingår i: Nature Genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 42:8, s. 71-692
-
Tidskriftsartikel (refereegranskat)abstract
- We performed a genome-wide association study on 1,292 individuals with abdominal aortic aneurysms (AAAs) and 30,503 controls from Iceland and The Netherlands, with a follow-up of top markers in up to 3,267 individuals with AAAs and 7,451 controls. The A allele of rs7025486 on 9q33 was found to associate with AAA, with an odds ratio (OR) of 1.21 and P = 4.6 x 10(-10). In tests for association with other vascular diseases, we found that rs7025486[A] is associated with early onset myocardial infarction (OR = 1.18, P = 3.1 x 10(-5)), peripheral arterial disease (OR = 1.14, P = 3.9 x 10(-5)) and pulmonary embolism (OR = 1.20, P = 0.00030), but not with intracranial aneurysm or ischemic stroke. No association was observed between rs7025486[A] and common risk factors for arterial and venous diseases-that is, smoking, lipid levels, obesity, type 2 diabetes and hypertension. Rs7025486 is located within DAB2IP, which encodes an inhibitor of cell growth and survival.
|
|
